|
|
Financial Royalty Assets
|
1,960
|
2,065
|
2,125
|
|
|
Intangible Royalty Assets
|
143
|
171
|
37
|
|
|
Other royalty income
|
19
|
53
|
75
|
|
|
Revenues
|
2,122
|
2,289
|
2,237
|
|
|
Provision for Other Credit Losses
|
|
|
904
|
|
|
Research and Development Expense
|
26
|
200
|
177
|
|
|
Amortization of intangible assets
|
23
|
23
|
6
|
|
|
General and Administrative Expense
|
182
|
183
|
227
|
|
|
Asset Impairment Charges
|
|
|
616
|
|
|
Total operating expenses, net
|
527
|
859
|
1,930
|
|
|
Operating income
|
1,595
|
1,431
|
307
|
|
|
Equity in losses/(earnings) of equity method investees
|
44
|
-19
|
-9
|
|
|
Interest expense
|
157
|
166
|
188
|
|
|
(Gains)/losses on derivative financial instruments
|
-42
|
-22
|
97
|
|
|
Losses/(gains) on equity securities
|
247
|
-48
|
-33
|
|
|
Losses/(gains) on available for sale debt securities
|
|
18
|
-7
|
|
|
Interest income
|
28
|
54
|
78
|
|
|
Other non-operating expense, net
|
-33
|
-6
|
-15
|
|
|
Total other expenses/(income), net
|
107
|
-190
|
-77
|
|
|
Consolidated net income before tax
|
1,702
|
1,241
|
230
|
|
|
Consolidated net income
|
1,702
|
1,241
|
230
|
|
|
Net income attributable to non-controlling interests
|
727
|
621
|
187
|
|
|
Net income attributable to Royalty Pharma plc
|
975
|
620
|
43
|
|
|
Earnings Per Share, Basic
|
1.32
|
1.49
|
0.1
|
|
|
Earnings Per Share, Diluted
|
1.32
|
1.49
|
0.1
|
|
|
Basic (in shares)
|
375
|
415
|
438
|
|
|
Diluted (in shares)
|
375
|
415
|
438
|
